Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.
      QxMD      Google Scholar   
Citation:
Breast Cancer Res Treat vol 171 (2) 325-34
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
8
Parents:
2469  
Children:
None
Program:
CCP
Primary Committee:
Older Adult
Sec. Committees:
Breast    Health Outcomes    
Pharmas:
 
Grants:
UG1CA189823, 30CA033572, U10CA180790, U10CA180795, U10CA180820, CA180795, U10CA180836, U10CA180838, U10CA180857, U10CA180858, U10CA180867, U10CA180888, CA180858  
Corr. Author:
 
Authors:
                               
Networks:
CA043, LAPS-CT018, LAPS-IL057, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-TX035, NY018   
Study
CALGB-40503
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: